Differential effects of serum lipoprotein-associated phospholipase A2 on periventricular and deep subcortical white matter hyperintensity in brain
Junying Jiang¹#, Yuanyuan Gao²#, Rui Zhang¹, Lin Wang¹, Xiaoyuan Zhao¹, Qi Dai¹, Wei Zhang¹, Xiujian Xu¹, Xuemei Chen¹*
¹Department of Neurology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 211100, China
²Department of General practice, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, 211100, China
*Correspondence should be addressed to:
Xuemei Chen, Department of Neurology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 211100, China; Tel: +86-025-51191100; Email: 13347808579@189.cn.
# These authors contributed equally to this work.
Short title: Effects of Lp-PLA2 on PVWMH and DSWMH
Abstract
Background: High lipoprotein-associated phospholipase A2 (Lp-PLA2) was associated with white matter hyperintensity (WMH). There were differences in the anatomical structure and pathophysiological mechanism between periventricular WMH (PVWMH) and deep subcortical WMH (DSWMH). In this study, we aimed to investigate the effects of serum Lp-PLA2 on the PVWMH and DSWMH.

Methods: This cross-sectional study recruited 711 Chinese adults aged ≥45 years presented to the Department of Neurology, the Affiliated Jiangning Hospital of Nanjing Medical University between January 2016 and July 2019. Enzyme linked immunosorbent assay (ELISA) was utilized to determine the serum Lp-PLA2. Fazekas scale was used to measure the severity of PVWMH and DSWMH. Ordinal logistic regression analysis was carried out to investigate the relationship between serum Lp-PLA2 and PVWMH or DSWMH.

Results: A total of 567 cases were included in this study. Ordinal logistic regression analysis indicated that, after adjusting for the confounding variables, there was a lower risk of PVWMH in the patients with normal and moderately elevated serum Lp-PLA2 compared with those with significantly elevated serum Lp-PLA2. In addition, PVWMH was correlated to advanced age, hypertension, diabetes mellitus, and lacunar infarction. DSWMH was correlated to advanced age and lacunar infarction. There was no correlation between serum Lp-PLA2 and DSWMH.

Conclusions: Serum Lp-PLA2 was closely associated with the pathogenesis of PVWMH rather than DSWMH. There might be different pathological mechanisms between PVWMH and DSWMH.

Key words: lipoprotein-associated phospholipase A2; periventricular white matter hyperintensity; deep subcortical white matter hyperintensity; Fazekas score
**Background**

White matter hyperintensity (WMH), one the most common types of cerebral small vessel disease (CSVD) [1,2], is mainly diagnosed based on the presence of hyperintensity on T2-weighted sequences, isointensity or hypointensity on T1-weighted signals unlike cerebrospinal fluid. It is depending on the sequence parameters and the severity of pathological changes [3]. To date, WMH shows a high prevalence in the aged population [4-6], which aggravates the decline in the cognitive function [2,7,8], post-stroke functional injuries [9,10], recurrence of stroke [9], as well as post-stroke mortality [2,11]. Meanwhile, it is associated with the gait, balance [12] and emotional decline [2,13]. Therefore, it is necessary to screen the risk factors associated with the pathogenesis of WMH.

Previous studies confirmed a relationship between inflammation and pathogenesis of WMH [14-16]. Recently, a prospective study involving 15,792 adults aged between 45 and 65 years, midlife inflammation may lead to deterioration of WMH among the aged population [17]. As an enzyme secreted by the circulating macrophages, lipoprotein-associated phospholipase A2 (Lp-PLA2) participated in the low density lipoprotein metabolism, contributed to the onset of atherosclerosis, and mediated the inflammation [18,19]. In a previous study, Lp-PLA2 concentration was associated with the increased burden of WMH.

According to the lesion sites, WMH could be divided into periventricular WMH (PVWMH) and deep subcortical WMH (DSWMH) [20]. Generally, these two types of WMH are usually simultaneously developed and progressed. Nevertheless, increasing studies indicated that PVWMH and DSWMH showed various anatomical and histopathological changes, which demonstrated that there might differences in their pathogenesis [20,21]. To date, no studies focused on the effects of serum Lp-PLA2 levels on the variations between PVWMH and DSWMH. In this study, we aimed to determine the impacts of serum Lp-PLA2 level on the onset of PVWMH and DSWMH.

**Materials and methods**

**Subjects**

In this study, we included 711 cases received physical examination in the Department of Neurology, the Affiliated Jiangning Hospital of Nanjing Medical University due to dizziness and headache between January 2016 and July 2019. A total of 635 subjects aged ≥45 years received cerebral magnetic resonance imaging (MRI) met the inclusion criteria. The exclusion criteria were as follows: those with acute or chronic infectious diseases or rheumatic diseases, or those that may affect the evaluation of WMH; those with severe head injury, severe cerebral infarction, cerebral hemorrhage, multiple sclerosis or brain malignancy. The study flowchart was shown in Fig 1. Each subject signed the informed consent. The study protocols were approved by the Ethical Committee of Affiliated Jiangning Hospital of Nanjing Medical University.

**Data collection**

The risk factors for cardiovascular diseases were collected from each subject, including clinical and demographic information. The information consisted of age, gender, hypertension, diabetes mellitus, coronary heart disease, atrial fibrillation, lacunar infarction, smoking, drinking alcohol, as well as formation of carotid artery plaque. In addition, laboratory tests were carried out to determine the fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), homocysteine (Hcy), Lp-PLA2, high-sensitive C-reactive protein (H-CRP), urea as well as creatinine. All the samples were collected from the venous blood of the subjects in a fasting state for 12 hrs. The serum Lp-PLA2 concentration was determined using the ELISA method, and was divided into normal range (<200 μg/L), moderate elevation (200-223 μg/L) and significant elevation (≥223 μg/L).
according to the previous description [22]. Immunoturbidimetry was used to determine the level of H-CRP, and the concentration of Hcy was determined using the enzymatic method. The diagnosis of carotid artery plaque was given based on the local intima media thickness (IMT) of >1.2 mm or a 1.5-fold or more to the peripheral IMT. The site for the quantification of IMT measurement was chosen in the area with a distance of about 1.5 cm to the carotid bifurcation [23].

Cranial MRI collection and WMH

For the collection of cranial MRI, the MRI was performed using a 3.0T system, equipped with 8-channel coil arrays (Ingenia, Philips Medical System). MRI consisted of T1-weighted image, T2-weighted image, FLAIR image and DWI findings. The MRI features were evaluated by two experienced doctors specialized in the radiation that were blinded to the study design and grouping.

For the WMH, there were hyperintensity on T2-weighted images or FLAIR images in the lateral ventricle and subcortex region. WMH was confirmed in the presence of isointensity or hypointensity on T1-weighted signals [3]. WHM was evaluated using the Fazekas scale [24]. In the Fazekas scale, the lesions in the PVWMH and DSWMH were evaluated separately. Specifically, the PVWMH score standards were as follows: 0, loss; 1, calyptriform or pencil-like lamella; 2, smooth halo; 3, irregular hypertense signals near the ventricle extending to the deep white matter. The DSWMH score standards were as follows: 0, loss; 1, punctiform lesions; 2, initial fusion in the lesions; 3, massive fusion in the lesions (Fig 2).

Statistical analysis

All the continuous data were presented as mean ± standard deviation, or the median (quartile). The categorical data were presented as the percentage. The continuous variables that were normally distributed were analyzed using the one-factor analysis of variance, while these that were not normally distributed were analyzed using the non-parametric test. The categorical variables were analyzed using the Chi square test. The independent risk factors for PVWMH and DSWMH were measured using the odds ratio (OR) or 95% confidential interval (95% CI), based on the ordinal logistic regression analysis. SPSS 21.0 software was utilized for the statistical analysis. P<0.05 was considered to be statistically significant.

Results

Characteristics of the subjects

In total, 711 subjects were enrolled at first, among which 567 (male: 293; female: 274; median age: 65.51±9.86 years) were finally included in this study. All the 567 subjects received Fazekas score evaluation. Finally, 468 cases (82.54%) were diagnosed with WMH, including 432 (76.19%) with PVWMH and 378 (66.66%) with DSWMH. Among these cases, 340 (59.96%) showed serum Lp-PLA2 of <200 μg/L, 26 (4.59%) showed serum Lp-PLA2 in a range of 200-223 μg/L, and the rest 201 (35.45%) showed serum Lp-PLA2 of ≥223 μg/L (Table 1).

One-factor analysis for PVWMH and DSWMH

According to the PVWMH grouping, 135 subjects showed a Fazekas score of 0, 251 showed a score of 1, 107 showed a score of 2, and 74 showed a score of 3. There were statistical differences in the age, hypertension, diabetes mellitus, atrial fibrillation, lacunar infarction, Lp-PLA2 grade, creatinine, Hcy and H-CRP (P<0.05, Table 2). For the DSWMH grouping, 189 subjects showed a Fazekas score of 0, 244 showed a score of 1, 84 showed a score of 2, and 50 showed a score of 3. There were statistical differences in the age, hypertension, diabetes mellitus, lacunar infarction, Lp-PLA2 grade, TG and Hcy (P<0.05, Table 3).

Independent correlation factors for PVWMH
To further evaluate the correlation factors for PVWMH and DSWMH, we established an ordinal logistic regression model for the factors that may affect the PVWMH and DSWMH. Prior to the establishing of ordinal logistic regression model for PVWMH, we then performed the fitting test for the model ($\chi^2=261.40$, $P<0.001$) and the linear hypothesis test ($P=0.148$), which showed that the model showed good fitting. Ordinal logistic regression analysis indicated that there was a lower risk of PVWMH in the patients with normal and moderately elevated serum Lp-PLA2 compared with those with significantly elevated serum Lp-PLA2 (normal Lp-PLA2: OR 0.946, 95% CI 0.669-1.335; moderate Lp-PLA2: OR 0.305, 95% CI 0.134-0.696) after adjusting for the confounding variables. In addition, PVWMH grade was positively correlated with the advanced age (OR 1.089, 95% CI 1.067-1.110), hypertension (OR 1.614, 95% CI 1.105-2.358), diabetes mellitus (OR=1.579, 95% CI 1.078-2.314), as well as lacunar infarction (OR 5.155, 95% CI 3.540-7.508, Table 4).

Independent correlation factors for DSWMH

After fitting test and linear hypothesis test, ordinal logistic regression analysis indicated a good fitting for the DSWMH (fitting test: $\chi^2=198.546$, $P<0.001$; linear hypothesis test: $P=0.136$). Ordinal logistic regression analysis indicated that there was a positive correlation between DSWMH and advanced age (OR 1.081, 95% CI 1.061-1.102) and lacunar infarction (OR 3.823, 95% CI 2.662-5.490, Table 5).

Discussion

Rare studies investigated the correlation between serum Lp-PLA2 and WMH. Previously, Lp-PLA2 was reported to associate with the WMH [25,26]. However, no studies have been conducted to illustrate the roles of serum Lp-PLA2 on the sites of WMH. In this study, we investigated the effects of serum Lp-PLA2 on PVWMH and DSWMH in the elder population. Ordinal logistic regression analysis indicated that the patients with normal and moderately elevated serum Lp-PLA2 showed lower risks of developing PVWMH compared with those with significantly elevated serum Lp-PLA2. Our data revealed that statistical differences were merely observed between the patients with moderately and significantly elevated Lp-PLA2, which may be related to the fact that the sample size was not large. Moreover, no correlation was noticed between serum Lp-PLA2 and DSWMH. The serum Lp-PLA2 was independently correlated to the PVWMH rather than DSWMH. These findings indicated that Lp-PLA2 metabolic disorder played a crucial role in the pathogenesis of PVWMH.

WMH is featured by demyelination, loss of axon and gliosis [27]. To date, there are still disputes on the pathogenesis of WMH. Inflammation was considered to be associated with the pathogenesis of WMH, however, in some circumstances, inflammation is a biological response to the infection and injury [28]. Previously, inflammation was well accepted to be closely related to the pathogenesis of WMH [14-16]. In addition, there were regional variations in the effects of inflammation on the WMH. Inflammation was correlated with PVWMH rather than DSWMH [28], which was in line with our data. Compared with systemic inflammation biomarkers, there was a stronger correlation between vascular inflammation markers and WMH [28]. In addition, uni-variate analysis indicated a correlation between H-CRP and PVWMH. After adjusting age, hypertension, diabetes mellitus, atrial fibrillation and lacunar infarction, creatinine, Hcy, and phosphatidase A2, there was no correlation between H-CRP and PVWMH. Similarly, there was no correlation between H-CRP and DSWMH. Nevertheless, systemic inflammation may contribute to the pathogenesis of WMH in the elder population in a recent prospective study involving a large sample size. This implied that systemic inflammation was correlated with the progression of CSVD, especially in the conditions with persistent inflammation [17]. In future, further prospective cohort studies are required to illustrate the exact causes.
Lp-PLA2 is a type of enzyme involving in the hydrolysis of phosphoric oxide into oxidant fatty acids and lysophosphatidyl choline [23,25]. It was closely related to the ischemic stroke [29] or vascular dementia [30]. Besides, it contributed to the pathogenesis of atherosclerosis [31] and mediation of inflammation [29,32]. Moreover, it could mediate the vasculitis through regulating the metabolism of blood fat [33]. To our best knowledge, rare studies have been focused on the roles of Lp-PLA2 in the WMH. Elkind et al indicated that Lp-PLA2 was associated with the onset of WMH after investing 87 patients with WMH and lacunar infarction [25]. In a cross-sectional study involving 527 stroke-free subjects, Wright et al indicated that Lp-PLA2 was associated with a greater burden of WMH independent of H-CRP. However, that study did not investigate the potential effects of Lp-PLA2 on the WMH in different regions [19]. Our study indicated a correlation between elevation of serum Lp-PLA2 and PVWMH rather than DSWMH.

As is known to all, PVWMH usually occurs simultaneously with DSWMH. With the aging process, WMH usually happens in a single region of the white matter, which then progresses to another region, such as from the periventricular region to the deep subcortical region [20]. Our data indicated that serum Lp-PLA2 showed various effects on PVWMH and DSWMH, however, we could not explain the exact mechanism and causes. To date, little is known about why inflammation induces various effects on PVWMH or DSWMH. In the previous studies [3,21], PVWMH and DSWMH were considered to reflect various anatomical and histopathological features. In the anatomical view, there were anatomical differences between the arteriole in the peripheral ventricle and the deep subcortical region, however, the periventricular arteriola was superior to the deep subcortical arteriola in protecting the peripheral tissues from the vascular factors. In the histopathological views, DSWMH was likely to present more ischemic injuries, while PVWMH may involve in more inflammatory metabolism [34-36]. The inflammatory cascade reaction would trigger the endothelial dysfunction, which subsequently led to slight dysfunction of blood-brain barrier and WMH caused by tissue damages [27,37]. The calyptiform or smooth halo lesions in the peripheral ventricle were not originated from the ischemia. In fact, it was the subendymal gliosis and the demyelinated region beneath the ependyma lining. The deep subcortical punctiform signals, early fusion and fused white matter hypointensity indicated the gradual increase of the tissues with ischemic injuries, which was featured by slight perivascular lesions to massive axon loss, multiple small vacuoles and obvious arteriolosclerosis [34-36,38]. Therefore, these differences were tended to support the fact that serum Lp-PLA2 was more closely correlated to PVWMH rather than DSWMH.

Indeed, there are some limitations in this study. Firstly, we could not obtain a causal speculation based on these cross-sectional studies. Secondly, we only analyzed the circulating biomarkers at a certain time point. Therefore, prospective and longitudinal studies are required to illustrate the causal relationship between Lp-PLA2 and WMH. Thirdly, the Fazekas score was utilized for the grading of the WMH, without performing the quantification analysis.

Conclusions

Serum Lp-PLA2 was closely related to the pathogenesis of PVWMH rather than DSWMH. Our data indicated that there might be different pathological mechanisms between PVWMH and DSWMH. In addition, Lp-PLA2 played an important role in the pathogenesis and progression of PVWMH.

Abbreviation:

WMH, white matter hyperintensity; CSVD cerebral small vessel disease; Lp-PLA2, lipoprotein-associated phospholipase A2; PVWMH, periventricular white matter hyperintensity;
Acknowledgement:
Not applicable.

Competing interests:
The authors declare no competing interests.

Availability of data and material:
The data were available upon appropriate requests.

Ethics approval:
The study protocols were approved by the Ethical Committee of Affiliated Jiangning Hospital of Nanjing Medical University.

Consent to participate:
Not applicable.

Consent for publication:
Not applicable.

Funding:
This research was supported by Kangda College of Nanjing Medical University Science and Research Development Project, Jiangsu, China (KD2019KYJJYB047); Nanjing Medical Science and technique Development Foundation (QRX17032); Nanjing Medical University Science and Technology Development Project, Jiangsu, China (NMUB2019240).

Author contributions:
JJY and GYY: design of the study. ZR, WL, ZXY, ZW, DQ and XXJ: collection of data. GYY and JJY: statistical analysis. JJY, GYY, CXM: writing-review and editing of the drafts.
References

1. Soldan A, Pettigrew C, Zhu Y, et al. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease. Neurology. 2020 Mar; 394(9): e950-e960.

2. Rensma SP, van Sloten TT, Launer LJ, et al. Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2018 Jul;90:164-173.

3. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013 Aug; 12(8): 822-38.

4. T PS, Srikanth VK, Hubbard RE, et al. White matter hyperintensities and the progression of frailty - the Tasmanian Study of Cognition and Gait. J Gerontol A Biol Sci Med Sci. 2020 Jan 20.

5. Zhou YN, Gao HY, Zhao FF, et al. The study on analysis of risk factors for severity of white matter lesions and its correlation with cerebral microbleeds in the elderly with lacunar infarction. Medicine (Baltimore). 2020 Jan; 99(4): e18865.

6. Molloy CJ, Nugent S, Bokde ALW. Alterations in diffusion measures of white matter integrity associated with healthy aging. J Gerontol A Biol Sci Med Sci. 2019 Dec 12.

7. Knopman DS, Griswold ME, Lirette ST, et al. Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: atherosclerosis risk in communities-neurocognitive study. Stroke. 2015 Feb; 46(2): 433-40.

8. van den Berg E, Geerlings MI, Biessels GJ, et al. White Matter Hyperintensities and Cognition in Mild Cognitive Impairment and Alzheimer's Disease: A Domain-Specific Meta-Analysis. J Alzheimers Dis. 2018; 63(2): 515-527.

9. Zerna C, Yu AYX, Modi J, et al. Association of White Matter Hyperintensities With Short-Term Outcomes in Patients With Minor Cerebrovascular Events. Stroke. 2018 Apr; 49(4): 919-923.

10. Georgakis MK, Duering M, Wardlaw JM, et al. WMH and long-term outcomes in ischemic stroke: A systematic review and meta-analysis. Neurology. 2019 Mar; 1992(12): e1298-e1308.

11. Debette S, Schilling S, Duperron MG, et al. Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A Systematic Review and Meta-analysis. JAMA Neurol. 2019 Jan 1; 76(1): 81-94.

12. Pinter D, Ritchie SJ, Dougal F, et al. Impact of small vessel disease in the brain on gait and balance. Sci Rep. 2017 Jan 30; 7: 41637.

13. van Agtmaal MJM, Houben A, Pouwer F, et al. Association of Microvascular Dysfunction With Late-Life Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2017 Jul 1; 74(7): 729-739.

14. Satizabal CL, Zhu YC, Mazoyer B, et al. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology. 2012 Mar; 6; 78(10): 720-7.

15. Wersching H, Duning T, Lohmann H, et al. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology. 2010 Mar; 30; 74(13): 1022-9.

16. Altendahl M, Maillard P, Harvey D, et al. An IL-18-centered inflammatory network as a biomarker for cerebral white matter injury. PLoS One. 2020; 15(1): e0227835.

17. Walker KA, Power MC, Hoogeveen RC, et al. Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease: The Atherosclerosis Risk in...
35. Cai A, Zheng D, Qiu R, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers. 2013;34(5):323-31.

18. Romero JR, Preis SR, Beiser AS, et al. Lipoprotein phospholipase A2 and cerebral microbleeds in the Framingham Heart Study. Stroke. 2012 Nov;43(11):3091-4.

20. Lee KO, Woo MH, Chung D, et al. Differential Impact of Plasma Homocysteine Levels on the Periventricular and Subcortical White Matter Hyperintensities on the Brain. Front Neurol. 2019;10:1174.

21. Dhamoon MS, Cheung YK, Bagei A, et al. Periventricular White Matter Hyperintensities and Functional Decline. Journal of the American Geriatrics Society. 2018 Jan;66(1):113-119.

22. Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2012 Mar-Apr;18 Suppl 1:1-78.

23. Liu H, Yao Y, Wang Y, et al. Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study. J Cell Mol Med. 2018 Oct;22(10):5145-5150.

24. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987 Aug;149(2):351-6.

25. Zhu S, Wei X, Yang X, et al. Plasma Lipoprotein-associated Phospholipase A2 and Superoxide Dismutase are Independent Predictors of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment. Aging Dis. 2019 Aug;10(4):834-846.

26. Wright CB, Moon Y, Paik MC, et al. Inflammatory biomarkers of vascular risk as correlates of leukoaraiosis. Stroke. 2009 Nov;40(11):3466-71.

27. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019 Jul;18(7):684-696.

28. Low A, Mak E, Rowe JB, et al. Inflammation and cerebral small vessel disease: A systematic review. Ageing Res Rev. 2019 Aug;53:100916.

29. Zhou F, Liu Y, Shi H, et al. Relation between lipoprotein-associated phospholipase A2 mass and incident ischemic stroke severity. Neurol Sci. 2018 Sep;39(9):1591-1596.

30. van Oijen M, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 is associated with risk of dementia. Ann Neurol. 2006 Jan;59(1):139-44.

31. Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nature reviews Neurology. 2016 Oct;12(10):594-604.

32. Shoamanesh A, Preis SR, Beiser AS, et al. Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study. Neurology. 2015 Feb 24;84(8):825-32.

33. Huang F, Wang K, Shen J. Lipoprotein-associated phospholipase A2: The story continues. Med Res Rev. 2020 Jan;40(1):79-134.

34. Fernando MS, Simpson JE, Matthews F, et al. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke. 2006 Jun;37(6):1391-8.

35. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993 Sep;43(9):1683-9.
36. Kim KW, MacFall JR, Payne ME. Classification of white matter lesions on magnetic resonance imaging in elderly persons. Biological psychiatry. 2008 Aug 15;64(4):273-80.
37. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013 May;12(5):483-97.
38. Schmidt R, Schmidt H, Haybaeck J, et al. Heterogeneity in age-related white matter changes. Acta neuropathologica. 2011 Aug;122(2):171-85.
Figure legends
Fig 1 Study flowchart
Fig 2 Representative T2-FLAIR images illustrating Fazekas score.